Trial Profile

A Phase 1b/2a Study Assessing the Safety and Efficacy of Intraputamenal Dopaminergic Stem Cell Transplants in Patients With Idiopathic Parkinson's Disease

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RNDP 001 (Primary)
Indications Parkinson's disease
Focus Adverse reactions; First in man
Acronyms REPLACE
Sponsors Kenai Therapeutics

Most Recent Events

15 Dec 2025 According to a Kenai Therapeutics media release, RNDP-001 has also been granted Fast Track designation by the U.S. FDA.
15 Dec 2025 According to a Kenai Therapeutics media release, company announced that the first patient has been dosed in this trial.
15 Dec 2025 According to a Kenai Therapeutics media release, Initial safety, tolerability and brain imaging data from all 12 patients are expected in 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com